ClinicalTrials.gg
CompletedNCT00928304Updated Mar 5, 2014Results posted

Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.

A Phase 2 interventional study of Florbetaben (BAY94-9172) in Down Syndrome and Amyloid Beta-protein, sponsored by Life Molecular Imaging SA. Completed at 2 sites in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-03-05.

Sponsored by Life Molecular Imaging SA (part of Lantheus Holdings, Inc.) · Phase 2, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
109
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 205 studies in Down Syndrome with a site in United States — 48 open to participants now, 56 under way, 4 of them phase 3. Down Syndrome · United States.

Enrollment
29th of 131
109 · median 40
Started
2009
with 10 others
Phase 2
23 of 205
8 open now
Registered
21st of 205
by date

Among the 205 studies in Down Syndrome with a site in United States, this one is the 29th largest by enrollment of the 131 interventional ones that give a count, is one of 11 that started in 2009, is one of 23 in phase 2, and was the 21st registered.

Down Syndrome

439 studies on the registry are indexed under Down Syndrome; 100 are open to participants now.

Browse Down Syndrome studies →

Open to participants now

48 of the 205 studies in Down Syndrome with a site in United States are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 58 (77%) stop at 75 or younger; 61 take children under 18; 19 take healthy volunteers.

This study: 21 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Down Syndrome with a site in United States, or all of them as a file.
02

Study summary

To determine the sensitivity of the visual assessment of BAY94-9172 PET images in detecting cerebral β-amyloid in individuals with Down Syndrome (DS) and specificity in individuals without DS. Given that individuals with Down Syndrome develop β-amyloid pathology over the age of 40, the clinical diagnosis of Down Syndrome will serve as the standard of truth.

03

Conditions studied

  • Down Syndrome
  • Amyloid Beta-protein

Keywords

  • Amyloid beta-protein
  • Down Syndrome
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Study participants were individuals with DS and healthy volunteers (HVs).

  • Main inclusion criteria for individuals without DS

    • >=21 and \<= 40 years of age
    • (MMSE) >= 28
    • Clinical Dementia Rating (CDR) of 0
  • Main inclusion criteria for individuals with DS

    • >= 40 years of age

Exclusion criteria

Exclusion Criteria:

  • Main exclusion criteria for both groups

    • Unstable medical or psychiatric condition, study specific screening procedures with the understanding that the patient has the right to withdraw from the study at any time
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
109 participants (actual)

Study arms

  • Experimental
    Florbetaben (BAY94-9172)

    Drug: Florbetaben (BAY94-9172)

Interventions

06

What researchers measure

Primary outcomes

  1. Sensitivity of the Independent Visual Assessment of Detecting Cerebral Amyloid-beta in Individuals With Down Syndrome and Specificity in Subjects Without Down Syndrome

    The primary variables are sensitivity (percentage of DS subjects positive for cerebral beta-amyloid) and specificity (percentage of healthy volunteers negative for cerebral beta-amyloid) of brain uptake of florbetaben based on the majority read of the visual assessment by three independent blinded readers of PET images obtained 100 to 120 minutes post-injection of florbetaben.

    Time frame: 100-120 min

Secondary outcomes

  1. Sensitivity Results in the Down Syndrome Age Subgroups

    The majority read sensitivity (percentage of DS subjects positive for cerebral beta-amyloid by majority read) was computed for the group of DS subjects with age equal to or below the median age (DS-young) and for DS subjects with age above the median age (DS-old). The median age was 46 yrs, with 3 subjects being exactly 46 yrs old. As defined, these subjects were assigned to the DS-young group.

    Time frame: 100 - 120 min

  2. Quantitative Parameters Standard Uptake Value Ratio

    The Standard Uptake Value Ratios for florbetaben signal in the frontal cortex, posterior cingulate, lateral temporal cortex, parietal cortex, and cerebellum (white matter) were determined as a quantitative measure of tracer uptake. The SUV is defined as the ratio of (1) the tissue radioactivity concentration c (in MBq/kg) at time point t, and (2) the injected activity (in MBq, extrapolated to the same time t) divided by the body weight (in kg). These SUV numbers from regions of interest were then used to derive SUV ratios (SUVR) using the SUV from the cerebellar cortex as reference.

    Time frame: 100 - 120 min p.i.

  3. Consistency Between Visual and Quantitative Efficacy

    For a comparison of the results of the visual assessment with the quantitative assessment, descriptive Standardized Uptake Value Ratio (SUVR) statistics were computed separately for DS subjects with an abnormal/normal majority read of the PET scan (DS-PET+/DS-PET-). The SUV is defined as the ratio of (1) the tissue radioactivity concentration c (in MBq/kg) at time point t, and (2) the injected activity (in MBq, extrapolated to the same time t) divided by the body weight (in kg). These SUV numbers from regions of interest were then used to derive SUV ratios (SUVR) using the SUV from the cerebellar cortex as reference.

    Time frame: 100 - 120 min

07

Results

Posted Jan 28, 2014

Participant flow

The study was conducted at two sites in the US.

Participant flow — Overall Study
MilestoneDown Syndrome GroupHealthy Volunteer Group
Started3970
Completed3970
Not completed00

Outcome measures

PrimarySensitivity of the Independent Visual Assessment of Detecting Cerebral Amyloid-beta in Individuals With Down Syndrome and Specificity in Subjects Without Down Syndrome

The primary variables are sensitivity (percentage of DS subjects positive for cerebral beta-amyloid) and specificity (percentage of healthy volunteers negative for cerebral beta-amyloid) of brain uptake of florbetaben based on the majority read of the visual assessment by three independent blinded readers of PET images obtained 100 to 120 minutes post-injection of florbetaben.

Time frame:
100-120 min
Reported as:
Number · percentage of subjects
Sensitivity of the Independent Visual Assessment of Detecting Cerebral Amyloid-beta in Individuals With Down Syndrome and Specificity in Subjects Without Down Syndrome
percentage of subjectsMajority Read
Sensitivity46.15 (30.51 to 61.80)
Specificity100.00 (100.00 to 100.00)
SecondarySensitivity Results in the Down Syndrome Age Subgroups

The majority read sensitivity (percentage of DS subjects positive for cerebral beta-amyloid by majority read) was computed for the group of DS subjects with age equal to or below the median age (DS-young) and for DS subjects with age above the median age (DS-old). The median age was 46 yrs, with 3 subjects being exactly 46 yrs old. As defined, these subjects were assigned to the DS-young group.

Time frame:
100 - 120 min
Reported as:
Number · percentage of subjects
Sensitivity Results in the Down Syndrome Age Subgroups
percentage of subjectsMajority Read (DS-Young)Majority Read (DS-Old)
Sensitivity Results in the Down Syndrome Age Subgroups23.81 (5.59 to 42.03)72.22 (51.53 to 92.91)
SecondaryQuantitative Parameters Standard Uptake Value Ratio

The Standard Uptake Value Ratios for florbetaben signal in the frontal cortex, posterior cingulate, lateral temporal cortex, parietal cortex, and cerebellum (white matter) were determined as a quantitative measure of tracer uptake. The SUV is defined as the ratio of (1) the tissue radioactivity concentration c (in MBq/kg) at time point t, and (2) the injected activity (in MBq, extrapolated to the same time t) divided by the body weight (in kg). These SUV numbers from regions of interest were then used to derive SUV ratios (SUVR) using the SUV from the cerebellar cortex as reference.

Time frame:
100 - 120 min p.i.
Reported as:
Mean · SUVR
Quantitative Parameters Standard Uptake Value Ratio
SUVRDown Syndrome GroupHealthy Volunteer Group
frontal cortex1.396 ± 0.24881.146 ± 0.0749
posterior cingulate1.525 ± 0.25491.329 ± 0.1118
lateral temporal cortex1.350 ± 0.22651.132 ± 0.0623
parietal cortex1.391 ± 0.25941.138 ± 0.0742
cerebellum, white matter1.730 ± 0.21151.769 ± 0.1302
SecondaryConsistency Between Visual and Quantitative Efficacy

For a comparison of the results of the visual assessment with the quantitative assessment, descriptive Standardized Uptake Value Ratio (SUVR) statistics were computed separately for DS subjects with an abnormal/normal majority read of the PET scan (DS-PET+/DS-PET-). The SUV is defined as the ratio of (1) the tissue radioactivity concentration c (in MBq/kg) at time point t, and (2) the injected activity (in MBq, extrapolated to the same time t) divided by the body weight (in kg). These SUV numbers from regions of interest were then used to derive SUV ratios (SUVR) using the SUV from the cerebellar cortex as reference.

Time frame:
100 - 120 min
Reported as:
Mean · SUVR
Consistency Between Visual and Quantitative Efficacy
SUVRDown Syndrome PET-positive (Majority Read)Down Syndrome PET-negative (Majority Read)Healthy Volunteer Group
frontal cortex1.566 ± 0.23721.249 ± 0.14511.146 ± 0.0749
posterior cingulate1.626 ± 0.23721.438 ± 0.24211.329 ± 0.1118
lateral temporal cortex1.498 ± 0.23961.223 ± 0.10921.132 ± 0.0623
parietal cortex1.557 ± 0.25671.250 ± 0.16201.138 ± 0.0742
cerebellum, white matter1.698 ± 0.23961.758 ± 0.18561.769 ± 0.1302

Adverse events

Collected over 8 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Down Syndrome Group—0/39 (0%)2/39 (5.1%)
Healthy Volunteer Group—0/70 (0%)5/70 (7.1%)
Most frequent other events
Most frequent other events
EventDown Syndrome GroupHealthy Volunteer Group
HeadacheNervous system disorders0/395/70
Injection site hematomaGeneral disorders2/391/70

Baseline characteristics

All Down Syndrome subjects and healthy volunteers enrolled into the study were included in the Baseline Analysis Population

Age, Categorical
Age, Categorical(Participants)Subjects Enrolled in Study
<=18 years0
Between 18 and 65 years109
>=65 years0
Age, Continuous
Age, Continuous(years)Subjects Enrolled in Study
Down Syndrome Group46.3 ± 4.7
Healthy Volunteer Group27.7 ± 5.1
Sex: Female, Male
Sex: Female, Male(Participants)Subjects Enrolled in Study
Female60
Male49
Region of Enrollment
Region of Enrollment(participants)Subjects Enrolled in Study
United States109
08

Study locations

2 sites
  • Sun City, Arizona 85351, United States
  • New Haven, Connecticut 06510, United States
09

References and documents

Publications

  • Bullich S, Roe-Vellve N, Marquie M, Landau SM, Barthel H, Villemagne VL, Sanabria A, Tartari JP, Sotolongo-Grau O, Dore V, Koglin N, Muller A, Perrotin A, Jovalekic A, De Santi S, Tarraga L, Stephens AW, Rowe CC, Sabri O, Seibyl JP, Boada M. Early detection of amyloid load using 18F-florbetaben PET. Alzheimers Res Ther. 2021 Mar 27;13(1):67. doi: 10.1186/s13195-021-00807-6. PubMed 33773598 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2014, 3 years after primary completion. A results delay was requested in May 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2009
First posted
Jun 25, 2009
Start
Jun 2009
Primary completionActual
Jan 2011
CompletionActual
Jan 2011
Results delay requested
May 9, 2013
Results first posted
Jan 28, 2014
Last update
Mar 5, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00928304
Responsible party
Sponsor
First posted
Jun 25, 2009
Start date
Jun 2009
Primary completion
Jan 2011
Completion
Jan 2011
Results posted
Jan 28, 2014
Last update
Mar 5, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Florbetaben f-18

Start the discussion